UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,214,690 B2
APPLICATION NO. : 10/080503
DATED : May 8, 2007
INVENTOR(S) : Higuchi et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

IN THE TITLE PAGES:

In Item [56] References Cited, in OTHER PUBLICATIONS:
in Venturoli et al., please replace "Prospectiove" with --Prospective--

IN THE SPECIFICATION:

At column 5, line 20, please replace structure

"



"

with the following structure: --



--

At column 9, line 34, please replace "A R^9" with --R^9--

At column 31, line 56-67, please replace structure

"



34

"

with the following structure: --



34

--

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,214,690 B2
APPLICATION NO. : 10/080503
DATED : May 8, 2007
INVENTOR(S) : Higuchi et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

IN THE CLAIMS:

Please replace Claims 1, 10, 24, 40, 57, and 58 with the following Claims:

1. A compound having the formula:



(I)

wherein:

R^1 is selected from the group consisting of hydrogen, F, Cl, Br, I, NO_2, OR^9, $NR^{10}R^{11}$, $S(O)_nR^9$, optionally substituted C_1–C_8 alkyl, optionally substituted C_1–C_8 haloalkyl, optionally substituted C_1–C_8 heteroalkyl, optionally substituted C_3–C_8 cycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted C_2–C_8 alkynyl and optionally substituted C_2–C_8 alkenyl;

R^2 is selected from the group consisting of hydrogen, F, Cl, Br, I, CF_3, CF_2Cl, CF_2H, CFH_2, CF_2OR^9, CH_2OR^9, OR^9, $S(O)_nR^9$, $NR^{10}R^{11}$, optionally substituted C_1–C_8 alkyl, optionally substituted C_1–C_8 haloalkyl, optionally substituted C_1–C_8 heteroalkyl, optionally substituted C_3–C_8 cycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted C_2–C_8 alkynyl and optionally substituted C_2–C_8 alkenyl;

R^3 and R^4 each independently is selected from the group consisting of hydrogen, OR^9, $S(O)_nR^9$, $NR^{10}R^{11}$, $C(Y)OR^{11}$, $CNR^{10}R^{11}$, optionally substituted C_1–C_8 alkyl, optionally substituted C_1–C_8 haloalkyl, optionally substituted C_1–C_8 heteroalkyl, optionally substituted C_3–C_8 cycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted C_2–C_8 alkynyl and optionally substituted C_2–C_8 alkenyl;

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

R^5 and R^6 each independently is selected from the group consisting of hydrogen, CF_3, CF_2Cl, CF_2H, CFH_2, optionally substituted C_1–C_8 alkyl, optionally substituted C_1–C_8 haloalkyl, optionally substituted C_1–C_8 heteroalkyl, optionally substituted C_3–C_8 cycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted C_2–C_8 alkynyl and optionally substituted C_2–C_8 alkenyl;

R^7 is selected from the group consisting of hydrogen, F, Cl, Br, I, optionally substituted C_1–C_8 alkyl, optionally substituted C_1–C_8 haloalkyl, optionally substituted C_1–C_8 heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl, OR^9, $S(O)_nR^9$, $NR^{10}R^{11}$, $C(Y)OR^{11}$ and $C(Y)NR^{10}R^{11}$;

R^8 is selected from the group consisting of hydrogen, F, Cl, Br, I, optionally substituted C_1–C_8 alkyl, optionally substituted C_1–C_8 haloalkyl, optionally substituted C_1–C_8 heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl, OR^9, $S(O)_nR^9$, $NR^{10}R^{11}$, $C(Y)OR^{11}$ and $C(Y)NR^{10}R^{11}$;

R^9 is selected from the group consisting of hydrogen, optionally substituted C_1–C_8 alkyl, optionally substituted C_1–C_8 haloalkyl, optionally substituted C_1–C_8 heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted arylalkyl;

R^{10} is selected from the group consisting of hydrogen, optionally substituted C_1–C_8 alkyl, optionally substituted C_1–C_8 haloalkyl, optionally substituted C_1–C_8 heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl, CO_2R^{12}, $C(O)R^{12}$, SO_2R^{12} and $S(O)R^{12}$;

R^{11} and R^{12} each independently is selected from the group consisting of hydrogen, optionally substituted C_1–C_8 alkyl, optionally substituted C_1–C_8 haloalkyl, optionally substituted C_1–C_8 heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl and optionally substituted arylalkyl;

R^{13} is selected from the group consisting of optionally substituted C_1–C_8 alkyl, optionally substituted C_1–C_8 haloalkyl, optionally substituted C_1–C_8 heteroalkyl, optionally substituted C_2–C_8 alkenyl, optionally substituted C_2–C_8 alkynyl, optionally substituted C_3–C_8 cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl and optionally substituted heteroarylalkyl;

m is selected from the group consisting of 0, 1 and 2;

n is selected from the group consisting of 0, 1 and 2;

W is selected from the group consisting of NH, $N\{R^{13}\}$, $N\{C(Y)R^{11}\}$ and $N\{SO_2R^{11}\}$;

X is O;

Z is selected from the group consisting of NH, $N\{R^{11}\}$, $N\{C(Y)R^{11}\}$, $N\{SO_2R^{12}\}$ and $N\{S(O)R^{12}\}$; and

Y is O;

and pharmaceutically acceptable salts thereof; wherein:

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

the substituents of an optionally substituted group comprise one or more substituents independently selected from among alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, haloalkenyl, haloalkynyl, cycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, alkoxy, aryloxy, haloalkoxy, amino, alkylamino, dialkylamino, alkylthio, arylthio, heteroarylthio, oxo, carboxyester, carboxamido, acyloxy, hydrogen, F, Cl, Br, I, CN, NO_2, NH_2, N_3, $NHCH_3$, $N(CH_3)_2$, SH, SCH_3, OH, OCH_3, OCF_3, CH_3, CF_3, $C(O)CH_3$, CO_2CH_3, CO_2H, $C(O)NH_2$, OR^9, SR^9, $NR^{10}R^{11}$, CF_2CF_3, CH_2CH_2F and CH_2CF_3.

10. The compound of claim 1, wherein:

R^1 is selected from the group consisting of hydrogen, F, Cl, Br, I, NO_2, OR^9, $NR^{10}R^{11}$, $S(O)_nR^9$, C_1–C_8 alkyl, C_1–C_8 haloalkyl, C_1–C_8 heteroalkyl, C_3–C_8 cycloalkyl, aryl, arylalkyl, heteroaryl, C_2–C_8 alkynyl and C_2–C_8 alkenyl;

R^2 is selected from the group consisting of hydrogen, F, Cl, Br, I, CF_3, CF_2Cl, CF_2H, CFH_2, CF_2OR^9, CH_2OR^9, OR^9, $S(O)_nR^9$, $NR^{10}R^{11}$, C_1–C_8 alkyl, C_1–C_8 haloalkyl, C_1–C_8 heteroalkyl, C_3–C_8 cycloalkyl, aryl, arylalkyl, heteroaryl, C_2–C_8 alkynyl and C_2–C_8 alkenyl;

R^3 and R^4 each independently is selected from the group consisting of hydrogen, OR^9, $S(O)_nR^9$, $NR^{10}R^{11}$, $C(Y)OR^{11}$, $C(Y)NR^{10}R^{11}$, C_1–C_8 alkyl, C_1–C_8 haloalkyl, C_1–C_8 heteroalkyl, C_3–C_8 cycloalkyl, aryl, arylalkyl, heteroaryl, C_2–C_8 alkynyl and C_2–C_8 alkenyl;

R^5 and R^6 each independently is selected from the group consisting of hydrogen, CF_3, CF_2Cl, CF_2H, CFH_2, C_1–C_8 alkyl, C_1–C_8 haloalkyl, C_1–C_8 heteroalkyl, C_3–C_8 cycloalkyl, aryl, arylalkyl, heteroaryl, C_2–C_8 alkynyl and C_2–C_8 alkenyl;

R^7 is selected from the group consisting of hydrogen, F, Cl, Br, I, C_1–C_8 alkyl, C_1–C_8 haloalkyl, C_1–C_8 heteroalkyl, aryl, heteroaryl, OR^9, $S(O)_nR^9$, $NR^{10}R^{11}$, $C(Y)OR^{11}$ and $C(Y)NR^{10}R^{11}$;

R^8 is selected from the group consisting of hydrogen, F, Cl, Br, I, C_1–C_8 alkyl, C_1–C_8 haloalkyl, C_1–C_8 heteroalkyl, aryl, heteroaryl, OR^9, $S(O)_nR^9$, $NR^{10}R^{11}$, $C(Y)OR^{11}$ and $C(Y)NR^{10}R^{11}$;

R^9 is selected from the group consisting of hydrogen, C_1–C_8 alkyl, C_1–C_8 haloalkyl, C_1–C_8 heteroalkyl, aryl, heteroaryl and arylalkyl;

R^{10} is selected from the group consisting of hydrogen, C_1–C_8 alkyl, C_1–C_8 haloalkyl, C_1–C_8 heteroalkyl, aryl, heteroaryl, arylalkyl, CO_2R^{12}, $C(O)R^{12}$, SO_2R^{12} and $S(O)R^{12}$;

R^{11} and R^{12} each independently is selected from the group consisting of hydrogen, C_1–C_8 alkyl, C_1–C_8 haloalkyl, C_1–C_8 heteroalkyl, aryl, heteroaryl, arylalkyl;

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

R^{13} is selected from the group consisting of C_1–C_8 alkyl, C_1–C_8 haloalkyl, C_1–C_8 heteroalkyl, C_2–C_8 alkenyl, C_2–C_8 alkynyl, C_3–C_8 cycloalkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl;

m is selected from the group consisting of 0, 1 and 2;

n is selected from the group consisting of 0, 1 and 2;

W is selected from the group consisting of NH, $N\{R^{13}\}$, $N\{C(Y)R^{11}\}$ and $N\{SO_2R^{11}\}$;

X is O;

Z is selected from the group consisting of NH, $N\{R^{11}\}$, $N\{C(Y)R^{11}\}$, $N\{SO_2R^{12}\}$ and $N\{S(O)R^{12}\}$; and

Y is O;

and pharmaceutically acceptable salts thereof.

24. A compound according to claim 23, wherein R^9 is selected from the group consisting of hydrogen and optionally substituted C_1–C_4 alkyl.

40. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula:



(I)

wherein:

R^1 is selected from the group consisting of hydrogen, F, Cl, Br, I, NO_2, OR^9, $NR^{10}R^{11}$, $S(O)_nR^9$, optionally substituted C_1–C_8 alkyl, optionally substituted C_1–C_8 haloalkyl, optionally substituted C_1–C_8 heteroalkyl, optionally substituted C_3–C_8 cycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted C_2–C_8 alkynyl and optionally substituted C_2–C_8 alkenyl;

R^2 is selected from the group consisting of hydrogen, F, Cl, Br, I, CF_3, CF_2Cl, CF_2H, CFH_2, CF_2OR^9, CH_2OR^9, OR^9, $S(O)_nR^9$, $NR^{10}R^{11}$, optionally substituted C_1–C_8 alkyl, optionally substituted C_1–C_8 haloalkyl, optionally substituted C_1–C_8 heteroalkyl, optionally substituted C_3–C_8 cycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted C_2–C_8 alkynyl and optionally substituted C_2–C_8 alkenyl;

CERTIFICATE OF CORRECTION

PATENT NO. : 7,214,690 B2
APPLICATION NO. : 10/080503
DATED : May 8, 2007
INVENTOR(S) : Higuchi et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

R^3 and R^4 each independently is selected from the group consisting of hydrogen, OR^9, $S(O)_nR^9$, $NR^{10}R^{11}$, $C(Y)OR^{11}$, $C(Y)NR^{10}R^{11}$, optionally substituted C_1–C_8 alkyl, optionally substituted C_1–C_8 haloalkyl, optionally substituted C_1–C_8 heteroalkyl, optionally substituted C_3–C_8 cycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted C_2–C_8 alkynyl and optionally substituted C_2–C_8 alkenyl;

R^5 and R^6 each independently are selected from the group consisting of hydrogen, CF_3, CF_2Cl, CF_2H, CFH_2, optionally substituted C_1–C_8 alkyl, optionally substituted C_1–C_8 haloalkyl, optionally substituted C_1–C_8 heteroalkyl, optionally substituted C_3–C_8 cycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted C_2–C_8 alkynyl and optionally substituted C_2–C_8 alkenyl;

R^7 is selected from the group consisting of hydrogen, F, Cl, Br, I, optionally substituted C_1–C_8 alkyl, optionally substituted C_1–C_8 haloalkyl, optionally substituted C_1–C_8 heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl, OR^9, $S(O)_nR^9$, $NR^{10}R^{11}$, $C(Y)OR^{11}$ and $C(Y)NR^{10}R^{11}$;

R^8 is selected from the group consisting of hydrogen, F, Cl, Br, I, optionally substituted C_1–C_8 alkyl, optionally substituted C_1–C_8 haloalkyl, optionally substituted C_1–C_8 heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl, OR^9, $S(O)_nR^9$, $NR^{10}R^{11}$, $C(Y)OR^{11}$ and $C(Y)NR^{10}R^{11}$;

R^9 is selected from the group consisting of hydrogen, optionally substituted C_1–C_8 alkyl, optionally substituted C_1–C_8 haloalkyl, optionally substituted C_1–C_8 heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl and optionally substituted arylalkyl;

R^{10} is selected from the group consisting of hydrogen, optionally substituted C_1–C_8 alkyl, optionally substituted C_1–C_8 haloalkyl, optionally substituted C_1–C_8 heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl, CO_2R^{12}, $C(O)R^{12}$, SO_2R^{12} and $S(O)R^{12}$;

R^{11} and R^{12} each independently is selected from the group consisting of hydrogen, optionally substituted C_1–C_8 alkyl, optionally substituted C_1–C_8 haloalkyl, optionally substituted C_1–C_8 heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl and optionally substituted arylalkyl;

R^{13} is selected from the group consisting of optionally substituted C_1–C_8 alkyl, optionally substituted C_1–C_8 haloalkyl, optionally substituted C_1–C_8 heteroalkyl, optionally substituted C_2–C_8 alkenyl, optionally substituted C_2–C_8 alkynyl, optionally substituted C_3–C_8 cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl and optionally substituted heteroarylalkyl;

m is 1;

n is selected from the group consisting of 0, 1 and 2;

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

W is selected from the group consisting of NH, N{R^{13}}, N{C(Y)R^{11}} and N{SO_2R^{11}};

X is O;

Z is selected from the group consisting of NH, N{R^{11}}, N{C(Y)R^{11}}, N{SO_2R^{12}} and N{S(O)R^{12}}; and

Y is O;

and pharmaceutically acceptable salts thereof; wherein:

the substituents of an optionally substituted group comprise one or more substituents independently selected from among alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, haloalkenyl, haloalkynyl, cycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, alkoxy, aryloxy, haloalkoxy, amino, alkylamino, dialkylamino, alkythio, arylthio, heteroarylthio, oxo, carboxyester, carboxamido, acyloxy, hydrogen, F, Cl, Br, I, CN, NO_2, NH_2, N_3, $NHCH_3$, $N(CH_3)_2$, SH, SCH_3, OH, OCH_3, OCF_3, CH_3, CF_3, $C(O)CH_3$, CO_2CH_3, CO_2H, $C(O)NH_2$, OR^9, SR^9, $NR^{10}R^{11}$, CF_2CF_3, CH_2CH_2F and CH_2CF_3.

57. A compound selected from the group consisting of:

(3*R*)-2,3,4,7-Tetrahydro-3-methyl-10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]-quinolin-8-one;

(3*R*)-2,3,4,7-Tetrahydro-3,4-dimethyl-10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]-quinolin-8-one;

(3*R*)-4-Ethyl-2,3,4,7-tetrahydro-3-methyl-10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]-quinolin-8-one;

(3*R*)-2,3,4,7-Tetrahydro-3-methyl-4-(2,2,2-trifluoroethyl)-10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;

(3*R*)-2,3,4,7-Tetrahydro-3-methyl-4-propyl-10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]-quinolin-8-one;

(3*R*)-4-Allyl-2,3,4,7-tetrahydro-3-methyl-10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]-quinolin-8-one;

(3*R*)-3-Ethyl-2,3,4,7-tetrahydro-10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;

(3*R*)-3-Ethyl-2,3,4,7-tetrahydro-4-methyl-10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]-quinolin-8-one;

(3*R*)-3,4-Diethyl-2,3,4,7-tetrahydro-10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]-quinolin-8-one;

(3*R*)-3-Ethyl-2,3,4,7-tetrahydro-4-(2,2,2-trifluoroethyl)-10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;

(3*R*)-4-(2-Chloro-2,2-difluoroethyl)-3-ethyl-2,3,4,7-tetrahydro-10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;

CERTIFICATE OF CORRECTION

PATENT NO. : 7,214,690 B2
APPLICATION NO. : 10/080503
DATED : May 8, 2007
INVENTOR(S) : Higuchi et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

(3*R*)-4-(2,2-Difluoroethyl)-3-ethyl-2,3,4,7-tetrahydro-10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;

(3*R*)-3-Ethyl-2,3,4,7-tetrahydro-4-propyl-10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]-quinolin-8-one;

(3*R*)-4-Allyl-3-ethyl-2,3,4,7-tetrahydro-10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]-quinolin-8-one;

(3*R*)-3-Ethyl-2,3,4,7-tetraydro-4-isobutyl-10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]-quinolin-8-one;

(3*R/S*)-2,3,4,7-Tetrahydro-3-propyl-10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]-quinolin-8-one;

(3*R/S*)-2,3,4,7-Tetrahydro-4-methyl-3-propyl-10-(trifluoromethyl)-8*H*[1,4]oxazino-[2,3-*f*]quinolin-8-one;

(3*R/S*)-4-Ethyl-2,3,4,7-tetrahydro-3-propyl-4-(2,2,2-trifluoroethyl)-10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;

(3*R/S*)-2,3,4,7-Tetrahydro-3-propyl-4-(2,2,2-trifluoroethyl)-10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;

(3*R*)-2,3,4,7-Tetrahydro-3-isopropyl-10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]-quinolin-8-one;

(3*R*)-2,3,4,7-Tetrahydro-3-isopropyl-4-methyl-10-(trifluoromethyl)-8*H*-[1,4]oxazino-[2,3-*f*]quinolin-8-one;

(3*R*)-4-Ethyl-2,3,4,7-tetrahydro-3-isopropyl-10-(trifluoromethyl)-8*H*-[1,4]oxazino-[2,3-*f*]quinolin-8-one;

(3*R*)-2,3,4,7-Tetrahydro-3-isopropyl-4-(2,2,2-trifluoroethyl)-10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;

(3*R*)-4-(2-Chloro-2,2-difluoroethyl)-2,3,4,7-tetrahydro-3-isopropyl-10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;

(3*R*)-4-(2,2-Difluoroethyl)-2,3,4,7-tetrahydro-3-isopropyl-10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;

(3*R*)-4-Allyl-2,3,4,7-tetrahydro-3-isopropyl-10-(trifluoromethyl)-8*H*-[1,4]oxazino-[2,3-*f*]quinolin-8-one;

(3*R*)-2,3,4,7-Tetrahydro-3-phenyl-10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;

(3*R*)-2,3,4,7-Tetrahydro-3-phenyl-4-(2,2,2-trifluoroethyl)-10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;

(3*R*)-4-Cyclopropylmethyl-2,3,4,7-tetrahydro-3-phenyl-10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;

(3*R*)-3-Benzyl-2,3,4,7-tetrahydro-4-(2,2,2-trifluoroethyl)-10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

2,3,4,7-Tetrahydro-10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;
2,3,4,7-tetrahydro-4-(2,2,2-trifluoroethyl)-10-(trifluoromethyl)-8*H*-[1,4]oxazino [2,3-*f*]quinolin-8-one;
(7a*R*,10a*S*)-7,7a,8,9,10,10a-Hexahydro-1-(trifluoromethyl) -7-(2,2,2-trifluoroethyl)-4*H*-cyclopenta[5,6][1,4]oxazino[2,3-*f*]quinolin-3-one;
(7a*R*,10a*S*)-7-Ethyl-7,7a,8,9,10,10a-hexahydro-1-(trifluoromethyl) -4*H*-cyclopenta-[5,6][1,4]oxazino[2,3-*f*]quinolin-3-one;
(7a*R*,10a*S*)-7,7a,8,9,10,10a-Hexahydro-3-isopropoxy-1-(trifluoromethyl) -7-(2,2,2-trifluoroethyl)-4*H*-cyclopenta[5,6][1,4]oxazino[2,3-*f*]quinolin-3-one;
(±)-(2*S*,3*R*)-2,3,4,7-Tetrahydro-2,3-dimethyl-4-(2,2,2-trifluoroethyl) -10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;
(6a*R*)-6a,7,8,9-Tetrahydro-4-(trifluoromethyl)-1*H*,6*H*-pyrrolo[1',2':4,5][1,4] -oxazino[2,3-*f*]quinolin-2-one;
2,3,4,7-Tetrahydro-2,2,4-trimethyl-10-(trifluoromethyl)-8*H*-[1,4]oxazino [2,3-*f*]-quinolin-8-one;
(3*R*)-8-Chloro-3-ethyl-3,4-dihydro-8-isopropoxy-4-(2,2,2-trifluoroethyl) -10-(trifluoromethyl)-2*H*-[1,4]oxazino[2,3-*f*]quinoline;
(3*R*)-3-Ethyl-3,4-dihydro-8-isopropoxy-8-methoxy-4-(2,2,2-trifluoroethyl) -10-(trifluoromethyl)-2*H*-[1,4]oxazino[2,3-*f*]quinoline;
(±)-2,3,4,7-Tetrahydro-4-(2,2,2-trifluoroethyl)-3,10-bis(trifluoromethyl) -8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;
(–)-2,3,4,7-Tetrahydro-4-(2,2,2-trifluoroethyl)-3,10-bis(trifluoromethyl) -8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;
(+)-2,3,4,7-Tetrahydro-4-(2,2,2-trifluoroethyl)-3,10-bis(trifluoromethyl) -8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;
(±)-2,3,4,7-Tetrahydro-3-(2,2,2-trifluoroethyl)-10-(trifluoromethyl)-8*H*-[1,4] oxazino[2,3-*f*]quinolin-8-one;
(±)-2,3,4,7-Tetrahydro-4-methyl-3-(2,2,2-trifluoroethyl)-10-(trifluoromethyl) -8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;
(±)-4-Ethyl-2,3,4,7-tetrahydro-3-(2,2,2-trifluoroethyl)-10-(trifluoromethyl) -8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;
(±)-2,3,4,7-Tetrahydro-3,4-bis(2,2,2-trifluoroethyl)-10-(trifluoromethyl) -8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;
(-)-2,3,4,7-Tetrahydro-3,4-bis(2,2,2-trifluoroethyl)-10-(trifluoromethyl) -8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;
(+)-2,3,4,7-Tetrahydro-3,4-bis(2,2,2-trifluoroethyl)-10-(trifluoromethyl -8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

(±)-4-Cyclopropylmethyl-2,3,4,7-tetrahydro-3-(2,2,2-trifluoroethyl) -10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;

(3*R*)-4-Cyclopropylmethyl-3-ethyl-2,3,4,7-tetrahydro-10-(trifluoromethyl) -8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;

(3*R*)-4-(2-Chloroethyl)-2,3,4,7-tetrahydro-3-isopropyl-10-(trifluoromethyl) -8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;

(±)-2,3,4,7-Tetrahydro-2-methyl-4-(2,2,2-trifluoroethyl)-10-(trifluoromethyl) -8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;

(3*R*)-3-Ethyl-4-(2-hydroxy-2-methylpropyl)-2,3,4,7-tetrahydro -10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one; and

(3*R*)-2,3,4,7-Tetrahydro-3-isobutyl-4-(2,2,2-trifluoroethyl)-10-(trifluoromethyl) -8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one; and

pharmaceutically acceptable salts thereof.

58. A compound selected from the group consisting of:

(3*R*)-2,3,4,7-Tetrahydro-3-methyl-4-(2,2,2-trifluoroethyl)-10-(trifluoromethyl) -8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;

(3*R*)-3-Ethyl-2,3,4,7-tetrahydro-4-(2,2,2-trifluoroethyl)-10-(trifluoromethyl) -8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;

(3*R*)-4-(2-Chloro-2,2-difluoroethyl)-3-ethyl-2,3,4,7-tetrahydro -10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;

(3*R*)-4-(2,2-Difluoroethyl)-3-ethyl-2,3,4,7-tetrahydro-10-(trifluoromethyl) -8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;

(3*R*)-2,3,4,7-Tetrahydro-3-isopropyl-4-(2,2,2-trifluoroethyl) -10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;

(3*R*)-4-(2-Chloro-2,2-difluoroethyl)-2,3,4,7-tetrahydro-3-isopropyl -10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;

(3*R*)-4-(2,2-Difluoroethyl)-2,3,4,7-tetrahydro-3-isopropyl-10-(trifluoromethyl) -8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;

(7a*R*,10a*S*)-7-Ethyl-7,7a,8,9,10,10a-hexahydro-1-(trifluoromethyl -4*H*-cyclopenta[5,6][1,4]oxazino[2,3-*f*]quinolin-3-one;

(7a*R*,10a*S*)-7-7a,8,9,10,10a-Hexahydro-1-(trifluoromethyl) -7-(2,2,2-trifluoroethyl)-4*H*-cyclopenta[5,6][1,4]oxazino[2,3-*f*]quinolin-3-one;

(±)-(2*S*,3*R*)-2,3,4,7-Tetrahydro-2,3-dimethyl-4-(2,2,2-trifluoroethyl) -10-(trifluoromethyl)-8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;

(±)-2,3,4,7-Tetrahydro-4-(2,2,2-trifluoroethyl)-3,10-bis(trifluoromethyl) -8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one;

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,214,690 B2
APPLICATION NO. : 10/080503
DATED : May 8, 2007
INVENTOR(S) : Higuchi et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

(–)-2,3,4,7-Tetrahydro-4-(2,2,2-trifluoroethyl)-3,10-bis(trifluoromethyl) -8*H*-[1,4]oxazino[2,3-*f*]quinolin-8-one; and
(+)-2,3,4,7-Tetrahydro-4-(2,2,2-trifluoroethyl)-3,10-bis(trifluoromethyl) -8*H*-[1,4]oxazino[2,3-*f*]quinolin-one; and
pharmaceutically acceptable salts thereof.

Signed and Sealed this

Seventeenth Day of June, 2008



JON W. DUDAS
Director of the United States Patent and Trademark Office